Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30, once-daily oral small molecule GLP-1R agonist and ASC39, once-daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results